Impax Laboratories, Inc. (IPXL) Shares Bought by SG Americas Securities LLC
SG Americas Securities LLC grew its holdings in Impax Laboratories, Inc. (NASDAQ:IPXL) by 161.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 92,880 shares of the specialty pharmaceutical company’s stock after purchasing an additional 57,326 shares during the period. SG Americas Securities LLC owned about 0.13% of Impax Laboratories worth $1,885,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. Maverick Capital Ltd. boosted its stake in shares of Impax Laboratories by 6,705.5% in the 2nd quarter. Maverick Capital Ltd. now owns 7,159,336 shares of the specialty pharmaceutical company’s stock worth $115,265,000 after buying an additional 7,054,136 shares during the last quarter. Fisher Asset Management LLC purchased a new position in shares of Impax Laboratories in the 3rd quarter worth $30,329,000. Dimensional Fund Advisors LP boosted its stake in shares of Impax Laboratories by 47.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,637,077 shares of the specialty pharmaceutical company’s stock worth $33,359,000 after buying an additional 845,375 shares during the last quarter. Balyasny Asset Management LLC boosted its stake in shares of Impax Laboratories by 357.7% in the 2nd quarter. Balyasny Asset Management LLC now owns 1,051,484 shares of the specialty pharmaceutical company’s stock worth $16,929,000 after buying an additional 821,734 shares during the last quarter. Finally, Stifel Financial Corp purchased a new position in shares of Impax Laboratories in the 2nd quarter worth $10,285,000. 86.09% of the stock is owned by institutional investors and hedge funds.
A number of equities analysts have recently issued reports on the company. Cowen Inc restated a “hold” rating and issued a $16.00 price target on shares of Impax Laboratories in a research note on Friday, November 10th. Cantor Fitzgerald raised their price target on Impax Laboratories from $25.00 to $35.00 and gave the stock an “overweight” rating in a research note on Friday, November 10th. UBS AG raised their price target on Impax Laboratories from $12.00 to $16.00 and gave the stock a “sell” rating in a research note on Monday, October 30th. Zacks Investment Research downgraded Impax Laboratories from a “hold” rating to a “sell” rating in a research note on Friday, October 20th. Finally, Royal Bank Of Canada set a $17.00 price target on Impax Laboratories and gave the stock a “hold” rating in a research note on Tuesday, October 17th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the company. Impax Laboratories has an average rating of “Hold” and an average price target of $19.60.
Impax Laboratories, Inc. (IPXL) opened at $17.05 on Friday. The firm has a market capitalization of $1,263.64, a price-to-earnings ratio of 25.07, a P/E/G ratio of 1.08 and a beta of 0.99. The company has a current ratio of 1.81, a quick ratio of 1.32 and a debt-to-equity ratio of 1.59. Impax Laboratories, Inc. has a 52-week low of $7.75 and a 52-week high of $25.70.
Impax Laboratories (NASDAQ:IPXL) last released its earnings results on Thursday, November 9th. The specialty pharmaceutical company reported $0.23 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.03. The company had revenue of $206.40 million for the quarter, compared to the consensus estimate of $208.38 million. Impax Laboratories had a positive return on equity of 9.06% and a negative net margin of 56.59%. Impax Laboratories’s quarterly revenue was down 9.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.37 earnings per share. equities analysts anticipate that Impax Laboratories, Inc. will post 0.63 EPS for the current fiscal year.
About Impax Laboratories
Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.
Want to see what other hedge funds are holding IPXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Impax Laboratories, Inc. (NASDAQ:IPXL).
Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.